




The New Global Standard in Aesthetics

Introducing LetbotulinumtoxinA—Uncompromising
precision for the modern practice.

The modern aesthetic practice demands predictability and economic viability.

- **The \$15.7B Market:** Rising demand for minimally invasive cosmetic procedures.
- **The Clinical Need:** Patients expect flawless, localized results with zero unintended muscle relaxation.
- **The Business Need:** Clinics require versatile dosing, premium quality, and sensible economics to drive practice growth.



Meet the smartly engineered 900 kDa LetibotulinumtoxinA.



- Derived from the pristine *Clostridium botulinum* CBFC26 strain.
- Designed for both aesthetic perfection and serious therapeutic applications.
- The smarter choice to bridge premium clinical outcomes with practice profitability.

Forged in the world's most competitive aesthetic landscape.

- **Hugel Heritage:** Innovating high-tech biomedical aesthetics since **2001**.
- **Market Dominance:** The **#1** market share in South Korea for **9** consecutive years.
- **Global Footprint:** Exporting the excellence of K-Beauty to over **70** countries worldwide.



Formulated for uncompromising 98% purity.



- **Advanced Vacuum-Drying:** Preserves maximum biological activity without the need for unnecessary preservatives.




- **Enzyme-Free Purification:** Advanced removal of remnant nucleic acids to minimize immunogenicity risks.



- **Predictable Potency:** High purity ensures a lower concentration of bacterial protein contaminants, protecting the patient's immune response over long-term treatments.

Highly predictable diffusion means total control for the injector.



Smaller anhidrotic area translates to localized efficacy with zero unintended muscle relaxation (e.g., ptosis). You hit exactly what you target.

Phase III clinical data proves strict non-inferiority to legacy neurotoxins.

88.49%

**LetibotulinumtoxinA
responders at week 4**

87.39%

**OnabotulinumtoxinA
responders at week 4**

Evaluated across rigorous BLESS I, II, III trials and extensive Phase III Chinese clinical trials (over 1,700 total subjects). LetibotulinumtoxinA delivers the exact aesthetic efficacy you and your patients expect.

Sustained results drive exceptional patient satisfaction.

92.888%

of patients self-reported the treatment as highly effective at week 4.

- **Fast Onset & Lasting Impact:** Meaningful aesthetic improvements sustained safely through 16 weeks of observation.
- **High tolerability** with no severe adverse drug reactions reported in comparative cosmetic studies.

The first and only South Korean brand to conquer the global 'Big 3'.

US FDA Approval (Feb 2024): Meeting the most stringent regulatory requirements in the world.

EU EMA Approval (2022): Validated across the European Union.

China NMPA (2020): Breaking into the massive Asian aesthetic market.

A rare regulatory milestone that guarantees world-class safety and quality.

State-of-the-art manufacturing ensures unmatched lot-to-lot consistency.

- **Produced** in Chuncheon, South Korea under strict global standards.
- **Fully certified:** Compliant with US cGMP and European EU GMP requirements.
- **Strict Internal Quality Control:** Maintains stable potency across every single vial, ensuring the 100th patient gets the exact same result as the first.



A versatile portfolio tailored exactly to your clinical workflow.



- **Available** in 50, 100, 150, 200, and the unique 300 Unit dosages.
- **Maximum Dosing Flexibility:** Choose the perfect vial for the treatment plan (from subtle facial aesthetics to larger body contouring).
- **Economic Efficiency:** Drastically reduces product waste and improves your clinic's bottom line.

Trusted beyond aesthetics in serious therapeutic medicine.

LetibotulinumtoxinA is a globally recognized medical solution with proven efficacy in:



Neurology

- Post-Stroke Upper Limb Spasticity



Pediatrics

- Dynamic Equinus Foot Deformity in Pediatric Cerebral Palsy



Ophthalmology & Beyond

- Benign Essential Blepharospasm
- Cervical Dystonia (Pipeline)

The smart choice for the modern aesthetic practice.

1

The K-Beauty Heritage: Backed by 9 consecutive years as the #1 market leader in South Korea.

2

Unmatched Precision: Proven in split-face trials to offer highly predictable, localized diffusion.

3

Global Validation: Fully vetted and approved by the US FDA, EU EMA, and China NMPA.


Premium clinical outcomes combined with powerful practice economics.

Clinical Excellence

- For the Patient: High-purity formulation, rapid onset, predictable results, and lasting satisfaction.

Practice Growth

- For the Practice: Versatile vial sizing eliminates waste, while competitive B2B economics widen your profit margins.



Upgrade your clinic's standard of care today.

- [LetibotulinumtoxinA](#) is now available for integration into your practice.
- Partner with Hugel to access premium products, comprehensive training programs, and dedicated clinical support.
- Reach out to your local distributor or visit [Hugel Aesthetics](#) to schedule a practice consultation.

